These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Compounded weight-loss medications such as those promoted in the Hims & Hers commercial aren’t approved by the FDA.

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

The GLP-1 receptor is present in the brain ... Ongoing clinical trials of semaglutide (Ozempic, Wegovy) -- including the GIPD trial in Parkinson's disease and the EVOKE study in Alzheimer's ...

While there are no studies documenting the number of physicians taking GLP-1s, a number of physicians told the Times that they've noticed many colleagues growing thinner and sharing similar eating ...

MORGANTOWN – WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...

Two examples of GLP-1 medications currently on the market include ... As a result, the makers of Ozempic created the brand name Wegovy, containing the active ingredient semaglutide, for weight ...

Because poor adherence to GLP-1 receptor agonists may limit the long ... Saxenda), semaglutide (Ozempic, Wegovy), or tirzepatide (Mounjaro, Zepbound) -- all of which hold indications for type ...

But virtual diabetes and weight management care changed when GLP-1 drug Wegovy was approved for weight loss in June 2021. As the drugs' popularity reached new heights, it became an expensive item ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.